<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: development activities on", fill: "#0f0"},
{source: "2: development activities on", target: "2: ZFP Therapeutics ", fill: "#0f0"},
{source: "2: ZFP Therapeutics ", target: "2: relatively", fill: "#0f0"},
{source: "2: relatively", target: "2: Enabling Technology ", fill: "#0f0"},
{source: "2: development activities on", target: "6: programs increase", fill: "#da70d6"},
{source: "6: programs increase", target: "6: financial risk", fill: "#da70d6"},
{source: "6: financial risk", target: "6: product failure", fill: "#da70d6"},
{source: "6: product failure", target: "6: significantly increase", fill: "#da70d6"},
{source: "6: significantly increase", target: "6: research expenditures", fill: "#da70d6"},
{source: "6: research expenditures", target: "6: may involve", fill: "#da70d6"},
{source: "6: may involve", target: "6: conflicts with", fill: "#da70d6"},
{source: "6: conflicts with", target: "6: collaborators", fill: "#da70d6"},
{source: "6: collaborators", target: "6: strategic partners", fill: "#da70d6"},
{source: "6: programs increase", target: "22: ZFP Therapeutic ", fill: "#de3163"},
{source: "22: ZFP Therapeutic ", target: "22: development investors will increasingly assess", fill: "#de3163"},
{source: "22: development investors will increasingly assess", target: "22: Companys ", fill: "#de3163"},
{source: "22: Companys ", target: "22: technology based on", fill: "#de3163"},
{source: "22: technology based on", target: "22: products into", fill: "#de3163"},
{source: "22: products into", target: "22: through clinical trials", fill: "#de3163"},
{source: "22: ZFP Therapeutic ", target: "24: collaborators may control aspects", fill: "#fff0f5"},
{source: "24: collaborators may control aspects", target: "24: clinical trials which could", fill: "#fff0f5"},
{source: "24: clinical trials which could", target: "24: commercialization", fill: "#fff0f5"},
{source: "24: collaborators may control aspects", target: "27: collaborative", fill: "#002366"},
{source: "27: collaborative", target: "27: partners withdraw support", fill: "#002366"},
{source: "27: partners withdraw support", target: "27: proposed products", fill: "#002366"},
{source: "27: proposed products", target: "27: development", fill: "#002366"},
{source: "27: development", target: "27: negatively affected", fill: "#002366"},
{source: "27: collaborative", target: "66: gene regulation", fill: "#e9967a"},
{source: "66: gene regulation", target: "66: gene modification technology", fill: "#e9967a"},
{source: "66: gene modification technology", target: "66: technology", fill: "#e9967a"},
{source: "66: technology", target: "66: relatively new", fill: "#e9967a"},
{source: "66: relatively new", target: "66: intended applications", fill: "#e9967a"},
{source: "66: intended applications", target: "66: would limit", fill: "#e9967a"},
{source: "66: would limit", target: "66: revenue opportunities", fill: "#e9967a"},
{source: "66: gene regulation", target: "START_HERE", fill: "#e9967a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Two-hybrid_screening">Two-hybrid screening</a></td>
      <td>Two-hybrid screening (originally known as yeast two-hybrid system or Y2H) is a molecular biology technique used to discover protein–protein interactions (PPIs) and protein–DNA interactions by testing for physical interactions (such as binding) between two proteins or a single protein and a DNA molecule, respectively.\nThe premise behind the test is the activation of downstream reporter gene(s) by the binding of a transcription factor onto an upstream activating sequence (UAS).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Zinc_finger">Zinc finger</a></td>
      <td>A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions (Zn2+) in order to stabilize the fold. It was originally coined to describe the finger-like appearance of a hypothesized structure from the African clawed frog (Xenopus laevis) transcription factor IIIA. However, it has been found to encompass a wide variety of differing protein structures in eukaryotic cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Zinc_finger_nuclease">Zinc finger nuclease</a></td>
      <td>Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain.   Zinc finger domains can be engineered to target specific desired DNA sequences and this enables zinc-finger nucleases to target unique sequences within complex genomes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_software">Collaborative software</a></td>
      <td>Collaborative software or groupware is application software designed to help people working on a common task to attain their goals. One of the earliest definitions of groupware is "intentional group processes plus software to support them".As regards available interaction, collaborative software may be divided into: real-time collaborative editing platforms that allow multiple users to engage in live, simultaneous and reversible editing of a single file (usually a document),  and version control (also known as revision control and source control) platforms, which allow separate users to make parallel edits to a file, while preserving every saved edit by every user as multiple files (that are variants of the original file).Collaborative software is a broad concept that overlaps considerably with computer-supported cooperative work (CSCW).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SANGAMO BIOSCIENCES INC      Item 1A  Risk Factors       We have increased the focus of our research and <font color="blue"><font color="blue">development</font> programs on</font>     human  <font color="blue">therapeutic</font>s, which may increase operating <font color="blue"><font color="blue">expenditure</font>s</font> and the     <font color="blue">uncertainty</font> of our business</td>
    </tr>
    <tr>
      <td>We are increasing the emphasis and focus of     our  research  and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font> on</font> <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>and have     <font color="blue">relatively</font> fewer resources invested in our <font color="blue"><font color="blue">Enabling Technology</font> </font>programs</td>
    </tr>
    <tr>
      <td>In     the short term, this change in resource <font color="blue">allocation</font> may reduce our revenues     and increase operating <font color="blue"><font color="blue">expenditure</font>s</font> due to larger financial outlays to fund     preclinical studies, <font color="blue">manufacturing</font>, and clinical research</td>
    </tr>
    <tr>
      <td>The transition     <font color="blue">will also increase</font> the <font color="blue">visibility</font> of our <font color="blue">lead <font color="blue">therapeutic</font> programs</font> and the     <font color="blue">potential impact on</font> the stock price of <font color="blue">news releases</font> relating to these     programs</td>
    </tr>
    <tr>
      <td>We are <font color="blue">conducting <font color="blue">proprietary</font> research</font> to discover <font color="blue">ZFP Therapeutic </font>product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">programs increase</font> our <font color="blue">financial risk</font> of <font color="blue">product failure</font>,     may  <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> increase</font> our research <font color="blue"><font color="blue">expenditure</font>s</font>, and <font color="blue">may involve</font>     <font color="blue">conflicts with</font> our <font color="blue">collaborators</font> and <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">proprietary</font>     research programs consist of <font color="blue">research which</font> is <font color="blue">funded solely by</font> the <font color="blue">Company     </font>and where the Company retains <font color="blue">exclusive rights</font> to <font color="blue"><font color="blue">therapeutic</font> products</font>     <font color="blue">generated by</font> the research</td>
    </tr>
    <tr>
      <td>This is in contrast to certain of our research     programs that may be <font color="blue">funded by corporate partners</font> and in which we may share     rights to any resulting products</td>
    </tr>
    <tr>
      <td>We have conducted <font color="blue">proprietary</font> research     since inception, however, in the past year, our strategy has shifted toward     placing greater emphasis on <font color="blue">proprietary</font> research and <font color="blue"><font color="blue">therapeutic</font> <font color="blue">development</font></font>     and we expect this <font color="blue">trend <font color="blue">will continue</font></font> in 2006 as we initiate our first     Phase 2 <font color="blue">clinical trial</font> and <font color="blue">bring new</font> <font color="blue"><font color="blue">ZFP Therapeutics</font> </font><font color="blue">into <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font><font color="blue">proprietary</font> research programs may not <font color="blue">generate corresponding</font>     revenue  and  may create <font color="blue">conflicts with</font> our <font color="blue">collaborators</font> or strategic     partners</td>
    </tr>
    <tr>
      <td>The <font color="blue">implementation</font> of this <font color="blue">strategy will involve substantially</font>     greater business risks, the <font color="blue">expenditure</font> of <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> greater funds than</font>     our <font color="blue">historic research <font color="blue">activities</font></font> and will require substantial <font color="blue">commitments</font> of     time from our <font color="blue">management</font> and staff</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">dis<font color="blue"><font color="blue">agreement</font>s</font> with</font> our <font color="blue">collaborators</font> or <font color="blue">strategic partners</font>     could develop <font color="blue">over rights</font> to our <font color="blue"><font color="blue">intellectual</font> property with respect</font> to our     <font color="blue">proprietary</font> research <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">conflict with</font> our <font color="blue">collaborators</font> or     strategic  partners  could  reduce  our  ability  to <font color="blue"><font color="blue">enter into</font> future</font>     <font color="blue">collaboration</font> or <font color="blue">strategic partnering <font color="blue"><font color="blue">agreement</font>s</font></font> and <font color="blue"><font color="blue">negatively</font> impact</font> our     relationship with existing <font color="blue">collaborators</font> and <font color="blue">strategic partners</font>, which could     reduce our revenue and delay or terminate our <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>We, and our partner, Edwards Lifesciences, have initiated Phase 1 clinical     trials in our <font color="blue">respective lead</font> <font color="blue">ZFP Therapeutic </font>programs, and <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>    have never before <font color="blue">been tested</font> in humans</td>
    </tr>
    <tr>
      <td>We have completed <font color="blue">enrollment</font> and     treatment  of  the patients in the first of these trials of SB-509 for     diabetic <font color="blue">neuropathy</font> and thus far have not observed any drug-related adverse     events</td>
    </tr>
    <tr>
      <td>However if our lead <font color="blue">ZFP Therapeutic </font>fails its <font color="blue">initial safety study</font>,     it  could  reduce  our  ability to <font color="blue">attract new investors</font> and corporate     partners</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2005, Sangamo filed an IND with the FDA for SB-509, a     ZFP TF <font color="blue">activator</font> of VEGF-A, for the treatment of mild to <font color="blue">moderate diabetic</font>     <font color="blue">neuropathy</font></td>
    </tr>
    <tr>
      <td>We have completed <font color="blue">enrollment</font> and treatment of a Phase 1, single     blind, dose-escalation trial to measure the <font color="blue">laboratory</font> and <font color="blue">clinical safety</font>     of SB-509 and reported that we did not observe dose-limiting toxicity or any     severe adverse drug-related events</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">present data from</font> this     trial in the first half of 2006 and to initiate a Phase 2 <font color="blue">clinical trial</font> of     SB-509  in the <font color="blue">second half</font> of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Edwards Lifesciences </font>also filed an     investigational new drug (IND) <font color="blue"><font color="blue">application</font> with</font> the US Food and Drug     Administration (FDA) on <font color="blue">February </font>10, 2004 and initiated a Phase 1 clinical     trial in humans in August, 2004 and a second in the first half of 2005</td>
    </tr>
    <tr>
      <td>The     first Phase 1 studies of a                                         23       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>ZFP  Therapeutic  will  be  a <font color="blue">highly visible test</font> of the Company’s ZFP     Therapeutic approach</td>
    </tr>
    <tr>
      <td>Since we have increased our focus on <font color="blue">ZFP Therapeutic </font>    research and <font color="blue">development</font>, investors will increasingly assess the value of     the Company’s <font color="blue"><font color="blue">technology</font> <font color="blue">based on</font></font> the continued progress of <font color="blue">ZFP Therapeutic </font>    <font color="blue">products into</font> and <font color="blue">through <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">initial safety study</font> of     our  lead  <font color="blue">therapeutic</font>  was  halted due to safety concerns, this would     <font color="blue">negatively</font> affect the value of the Company’s stock</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may control aspects of our <font color="blue"><font color="blue">clinical trial</font>s</font>, which could     result  in  delays and other obstacles in the <font color="blue">commercialization</font> of our     proposed  products</td>
    </tr>
    <tr>
      <td>For some programs we are <font color="blue"><font color="blue">dependent</font> on third party</font>     <font color="blue">collaborators</font> to design and conduct our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, if any of these <font color="blue">collaborative</font>     <font color="blue">partners withdraw support</font> for our programs or <font color="blue">proposed products</font> or otherwise     impair their <font color="blue">development</font>, our business could be <font color="blue">negatively</font> affected</td>
    </tr>
    <tr>
      <td>We  have  limited experience in conducting <font color="blue"><font color="blue">clinical trial</font>s</font>, and we may     <font color="blue">encounter unanticipated toxicity</font> or <font color="blue">adverse events</font> or fail to <font color="blue">demonstrate</font>     the efficacy, causing us to delay, suspend or terminate the <font color="blue">development</font> of     our <font color="blue">ZFP Therapeutics</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>may fail to show the desired     safety and efficacy in initial <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">successfully</font>     complete Phase 1 trials, the FDA will require <font color="blue">additional</font> Phase 2 and Phase 3     <font color="blue">clinical testing</font> which involves <font color="blue"><font color="blue">significant</font>ly</font> greater resources, <font color="blue">commitments</font>     and expertise that may require us to <font color="blue">enter into</font> a <font color="blue">collaborative</font> relationship     with  a  <font color="blue">pharmaceutical</font>  company  that would assume <font color="blue">responsibility</font> for     late-stage <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our potential <font color="blue"><font color="blue">therapeutic</font> products</font> are subject to a lengthy and uncertain     <font color="blue">regulatory</font> process,and we may <font color="blue">encounter unanticipated toxicity</font> or adverse     events or fail to <font color="blue">demonstrate</font> efficacy, causing us to delay, suspend or     teminate the the <font color="blue">development</font> of a <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>and if these potential     products  are not approved, we will not be able to <font color="blue">commercialize</font> those     products</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">must approve</font> any human <font color="blue"><font color="blue">therapeutic</font> products</font> before they     can be marketed in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The process for receiving <font color="blue">regulatory</font>     approval is long and uncertain, and a <font color="blue">potential product may</font> not withstand     the rigors of <font color="blue">testing under</font> the <font color="blue">regulatory</font> <font color="blue">approval process</font>es</td>
    </tr>
    <tr>
      <td>Before commencing <font color="blue"><font color="blue">clinical trial</font>s</font> in humans, we or our <font color="blue">commercial partner</font>     must submit an Investigational New Drug (IND) <font color="blue">application</font> to the FDA The     FDA has 30 days to <font color="blue">comment on</font> the IND If the FDA does not <font color="blue">comment on</font> the     IND, we or our <font color="blue">commercial partner</font> may begin <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Clinical trials are subject to <font color="blue">oversight by <font color="blue">institutional</font> <font color="blue">review board</font>s</font> and     the FDA In addition, our <font color="blue"><font color="blue">proposed clinical</font> studies will</font> require <font color="blue">review from</font>     the Recombinant DNA Advisory Committee, or RAC, which is the <font color="blue">advisory board</font>     to the National Institutes of Health, or NIH, focusing on <font color="blue"><font color="blue">clinical trial</font>s</font>     involving  <font color="blue">gene transfer</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will typically submit</font> a <font color="blue">proposed clinical</font>     protocol and other product-related information to the RAC three to six     <font color="blue">months prior</font> to the expected IND <font color="blue">filing date</font></td>
    </tr>
    <tr>
      <td>Clinical trials:         •  must be conducted in <font color="blue">conformance with</font> the FDA’s good <font color="blue">clinical practices</font>     ICH <font color="blue">guidelines</font> and other applicable regulations;         •  <font color="blue">must meet <font color="blue">requirements</font></font> for <font color="blue"><font color="blue">institutional</font> <font color="blue">review board</font> oversight</font>;          •   <font color="blue">must follow</font> Institutional Biosafety Committee (IBC) and NIH RAC     <font color="blue">guidelines</font> where applicable;         •  <font color="blue">must meet <font color="blue">requirements</font></font> for <font color="blue">informed consent</font>;         •  are subject to continuing FDA oversight;         •  may require large numbers of <font color="blue">test subjects</font>; and         •  may be <font color="blue">suspended by</font> our <font color="blue">commercial partner</font>, the FDA, or us at any time     if it is believed that the subjects <font color="blue">participating</font> in these trials are being     exposed to unacceptable health risks or if the FDA <font color="blue">finds <font color="blue">deficiencies</font></font> in the     IND or the conduct of these trials</td>
    </tr>
    <tr>
      <td>Clinical trials are lengthy and are <font color="blue">typically conducted</font> in <font color="blue">three sequential</font>     phases,  but the <font color="blue">phases may overlap</font> or be combined</td>
    </tr>
    <tr>
      <td>Each <font color="blue">trial must</font> be     reviewed and <font color="blue">approved by</font> an <font color="blue">in<font color="blue">dependent</font> ethics committee</font> or <font color="blue">institutional</font>     <font color="blue">review board</font> before it can begin</td>
    </tr>
    <tr>
      <td>Phase 1 usually involves the initial     <font color="blue">introduction</font> of the <font color="blue">investigational drug into healthy</font>                                         24       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>volunteers or patients to <font color="blue">evaluate certain factors</font>, including its safety,     dosage  tolerance and, if possible, to gain an <font color="blue">early indication</font> of its     <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>Phase 2  usually  <font color="blue">involves trials</font> in a limited patient     population to <font color="blue">evaluate dosage tolerance</font> and <font color="blue"><font color="blue">appropriate</font> dosage</font>, identify     <font color="blue">possible adverse effects</font> and <font color="blue">safety risks</font>, and <font color="blue">evaluate preliminarily</font> the     efficacy  of the drug for <font color="blue">specific <font color="blue">indications</font></font></td>
    </tr>
    <tr>
      <td>Phase 3 trials usually     <font color="blue">further evaluate clinical efficacy</font> and <font color="blue">test further</font> for <font color="blue">safety by using</font> the     drug in its final form in an <font color="blue">expanded patient population</font></td>
    </tr>
    <tr>
      <td>Later clinical     <font color="blue">trials may fail</font> to support the findings of earlier trials, which would     delay, limit or prevent <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>While we have stated our intention to file an <font color="blue">additional</font> IND <font color="blue">application</font>s     during the <font color="blue"><font color="blue">next several</font> years</font>, this is only a statement of intent, and we     may not be able to do so because the associated product <font color="blue">candidates</font> may not     meet the <font color="blue">necessary preclinical <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>In addition, there can be no     assurance that, once filed, an IND <font color="blue">application</font> will result in the actual     <font color="blue">initiation</font> of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be able to find acceptable patients or may experience delays in     <font color="blue">enrolling patients</font> for our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA or we may suspend our     <font color="blue"><font color="blue">clinical trial</font>s</font> at any time if either believes that we are exposing the     subjects <font color="blue">participating</font> in these trials to unacceptable health risks</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>or <font color="blue">institutional</font> <font color="blue">review board</font>s and/or <font color="blue">institutional</font> <font color="blue">biosafety</font> <font color="blue">committees</font> at     the medical <font color="blue">institutions</font> and healthcare <font color="blue">facilities</font> where we sponsor clinical     trials may suspend any trial <font color="blue">indefinitely</font> if they find <font color="blue">deficiencies</font> in the     conduct of these trials</td>
    </tr>
    <tr>
      <td>The FDA and <font color="blue">institutional</font> <font color="blue">review board</font>s may also     require large numbers of patients, <font color="blue">and the FDA </font>may require that we repeat a     <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>The results of early Phase 1 trials are <font color="blue">based on</font> a small number of patients     over  a short period of time, and our <font color="blue">success may</font> not be indicative of     results in a large number of patients or of long-term efficacy</td>
    </tr>
    <tr>
      <td>The results     in  <font color="blue">early phases</font> of <font color="blue">clinical testing</font> are <font color="blue">based upon</font> limited numbers of     patients and a limited follow-up period</td>
    </tr>
    <tr>
      <td>The primary end point of the     trial is clinical and <font color="blue">laboratory</font> safety, however we expect to be able to     collect some <font color="blue">preliminary efficacy data</font></td>
    </tr>
    <tr>
      <td>Typically, our Phase 1 clinical     trials for <font color="blue">indications</font> of safety enroll less than 50 patients</td>
    </tr>
    <tr>
      <td>We anticipate     that  our  Phase 2 <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">efficacy would typically enroll</font>     <font color="blue">approximately</font> 100 patients</td>
    </tr>
    <tr>
      <td>Actual results with more <font color="blue">data points may</font> not     confirm  favorable  results from our <font color="blue">earlier stage trials</font></td>
    </tr>
    <tr>
      <td>A number of     companies in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> industries</font> have suffered     <font color="blue"><font color="blue">significant</font> setbacks</font> in late stage <font color="blue"><font color="blue">clinical trial</font>s</font> even after achieving     promising results in earlier stage <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If a larger population     of patients does not experience positive results, or if these results do not     have a lasting effect, our <font color="blue">products may</font> not receive approval from the FDA     Failure  to <font color="blue">demonstrate</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of our gene based     products in larger patient <font color="blue">populations</font> could have a material adverse effect     on our business that would cause our stock price to decline <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether or when we will obtain <font color="blue">regulatory</font> approval to     <font color="blue">commercialize</font> our product <font color="blue">candidates</font>, therefore we <font color="blue">cannot predict</font> the timing     of  any  future  revenue  from  these  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">commercialize</font> any of our product <font color="blue">candidates</font> to <font color="blue">generate revenue until</font> the     <font color="blue">appropriate</font>  <font color="blue">regulatory</font>  <font color="blue">authorities</font>  have  reviewed  and approved the     <font color="blue">application</font>s for the product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the     <font color="blue">regulatory</font> agencies will complete their <font color="blue">review processes</font> in a <font color="blue">timely manner</font>     or that we will obtain <font color="blue">regulatory</font> approval for any <font color="blue">product candidate</font> that we     or  our <font color="blue">collaborators</font> develop</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of <font color="blue">regulatory</font> <font color="blue">requirements</font>     typically takes many years, is <font color="blue">dependent</font> upon the type, <font color="blue">complexity</font> and     novelty  of  the  product  and requires the <font color="blue">expenditure</font> of substantial     resources</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">approval process</font>es outside the <font color="blue">United States</font> include     all of the <font color="blue">risks associated with</font> the FDA <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>In addition, we     may  experience  delays or rejections <font color="blue">based upon</font> <font color="blue">additional</font> government     <font color="blue">regulation from future legislation</font> or <font color="blue">administrative action</font> or changes in     FDA <font color="blue">policy during</font> the period of <font color="blue">product <font color="blue">development</font></font>, <font color="blue"><font color="blue">clinical trial</font>s</font> and FDA     <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>Our <font color="blue">gene regulation</font> and <font color="blue"><font color="blue">gene modification</font> <font color="blue">technology</font></font> is <font color="blue">relatively</font> new, and     if we are unable to use this <font color="blue">technology</font> in all our intended <font color="blue">application</font>s, it     <font color="blue">would limit</font> our <font color="blue">revenue <font color="blue">opportunities</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> involves a <font color="blue">relatively</font>     new approach to <font color="blue">gene regulation</font> and <font color="blue">gene modification</font></td>
    </tr>
    <tr>
      <td>Although we have     generated ZFP TFs for hundreds of gene sequences, we have not created ZFP     TFs for all gene sequences and may not be able do so, which <font color="blue">could limit</font> the     usefulness of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, while we have <font color="blue">demonstrate</font>d the     function of engineered ZFP TFs in mammalian cell culture, yeast, insects,     plants, and animals, we have not yet done so in humans, and the failure to     do so <font color="blue">could restrict</font> our ability to develop <font color="blue"><font color="blue">commercially</font> <font color="blue">viable products</font></font></td>
    </tr>
    <tr>
      <td>If     we, and our <font color="blue">collaborators</font> or <font color="blue">strategic partners</font>, are unable to extend our     results to new <font color="blue">commercially</font> important genes, experimental animal                                         25       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>models, and <font color="blue">human clinical studies</font>, we may be unable to use our <font color="blue">technology</font>     in all its intended <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Also, delivery of <font color="blue">ZFP TFs and ZFNs </font>into     cells and organisms, including humans, in these and other <font color="blue">environments</font> is     limited  by  a  number of technical hurdles, which we may be unable to     surmount</td>
    </tr>
    <tr>
      <td>This is a particular challenge for <font color="blue">therapeutic</font> <font color="blue">application</font>s of our     <font color="blue">technology</font> that will require the use of <font color="blue">gene transfer</font> systems that may not     be  <font color="blue">effective</font>  for the delivery of our <font color="blue">ZFP TFs or ZFNs </font>in a particular     <font color="blue">therapeutic</font> <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The expected value and utility of our <font color="blue">ZFP TFs and ZFNs </font>is in part <font color="blue">based on</font>     our belief that the targeted or <font color="blue">specific regulation</font> of <font color="blue">gene expression</font> and     targeted  <font color="blue">gene modification</font> may enable us to develop a new <font color="blue">therapeutic</font>     <font color="blue">approach as well as</font> to <font color="blue">help <font color="blue">scientists</font> better</font> understand the role of human,     animal,  and  other  genes in disease and to aid their efforts in drug     <font color="blue">discovery</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We also believe that the regulation of gene     expression and <font color="blue">targeted gene insertion will</font> have utility in <font color="blue">agricultural</font>     <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Life <font color="blue">sciences companies</font> have developed or     <font color="blue">commercialize</font>d only a <font color="blue">few products</font> in any of these fields <font color="blue">based on</font> results     <font color="blue">from genomic research</font> or the ability to regulate <font color="blue">gene expression</font></td>
    </tr>
    <tr>
      <td>We, our     <font color="blue">collaborators</font>,  or  our  <font color="blue">strategic partners</font> may not be able to use our     <font color="blue">technology</font> to identify and <font color="blue">validate drug targets</font> or to develop commercial     products in the <font color="blue">intended markets</font></td>
    </tr>
    <tr>
      <td>We  are  currently  engaged  in  the research and <font color="blue">development</font> of a new     <font color="blue">application</font> of our <font color="blue">technology</font> platform: ZFP-mediated <font color="blue">gene modification</font> using     ZFNs  to  effect either gene <font color="blue">correction</font> or gene <font color="blue">disruption</font></td>
    </tr>
    <tr>
      <td>Using this     technique, Sangamo <font color="blue">scientists</font> have engineered ZFNs to cut DNA at a specific     site  within a <font color="blue">target gene</font>, and to then to either correct the <font color="blue">adjacent</font>     <font color="blue">sequences with newly synthesized</font> DNA <font color="blue">copied from</font> an introduced DNA template,     gene <font color="blue">correction</font>, or to rejoin the two ends of the <font color="blue">break which frequently</font>     results  in the <font color="blue">disruption</font> of the gene’s function</td>
    </tr>
    <tr>
      <td>In so doing, we are     attempting to “correct” an abnormal or disease-related mutation or DNA     sequence  or  to disrupt a gene that is involved in <font color="blue">disease pathology</font></td>
    </tr>
    <tr>
      <td>ZFP-mediated <font color="blue">gene modification</font> is at an <font color="blue">early stage</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">scientists</font> have shown ZFP-mediated <font color="blue">gene modification</font> to work in isolated     cells; however, a <font color="blue"><font color="blue">significant</font> amount</font> of <font color="blue">additional</font> research will be needed     before this technique can be evaluated in animals or plants and <font color="blue">subsequently</font>     tested for <font color="blue">application</font>s in <font color="blue">human healthcare</font> and <font color="blue">plant <font color="blue">agriculture</font></font></td>
    </tr>
    <tr>
      <td>We may be unable to license <font color="blue">gene transfer</font> <font color="blue">technologies</font> that we may need to     <font color="blue">commercialize</font> our ZFP TF <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In order to regulate a gene in a cell,     the  ZFP  TF or ZFN must be <font color="blue">efficiently</font> delivered to the cell</td>
    </tr>
    <tr>
      <td>We have     licensed  certain <font color="blue">gene transfer</font> <font color="blue">technologies</font> for use with our Enabling     Technologies, which are <font color="blue">ZFP TFs and ZFNs </font>used in <font color="blue">pharmaceutical</font> <font color="blue">discovery</font>     research and <font color="blue">protein production</font></td>
    </tr>
    <tr>
      <td>We are evaluating these systems and other     <font color="blue"><font color="blue">technologies</font> which may</font> need to be used in the delivery of <font color="blue">ZFP TFs or ZFNs </font>    into  cells  for  in vitro  and  in  vivo  <font color="blue">application</font>s, including ZFP     Therapeutics</td>
    </tr>
    <tr>
      <td>However, we may not be able to license the <font color="blue">gene transfer</font>     <font color="blue">technologies</font> required to develop and <font color="blue">commercialize</font> our <font color="blue">ZFP Therapeutics</font></td>
    </tr>
    <tr>
      <td>We     have not developed our own <font color="blue">gene transfer</font> <font color="blue">technologies</font>, and we rely on our     ability to <font color="blue">enter into</font> license <font color="blue"><font color="blue">agreement</font>s</font> to <font color="blue"><font color="blue">provide us with</font> rights</font> to the     necessary <font color="blue">gene transfer</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to obtain a license to use     gene  transfer <font color="blue">technologies</font> with entities which own such <font color="blue">technology</font> on     reasonable  commercial  terms,  if  at all, <font color="blue">could delay</font> or prevent the     preclinical evaluation, <font color="blue">clinical testing</font>, and/or <font color="blue">commercialization</font> of our     <font color="blue">therapeutic</font> product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We do not currently have the <font color="blue">infrastructure</font> or <font color="blue">capability</font> to <font color="blue">manufacture</font>     <font color="blue">therapeutic</font>  products  on  a  commercial  scale</td>
    </tr>
    <tr>
      <td>In  order  for us to     <font color="blue">commercialize</font> these <font color="blue">products directly</font>, we would need to develop, or obtain     <font color="blue">through outsourcing arrangements</font>, the <font color="blue">capability</font> to execute all of these     functions</td>
    </tr>
    <tr>
      <td>If we are unable to develop or otherwise obtain the requisite     preclinical, clinical, <font color="blue">regulatory</font>, <font color="blue">manufacturing</font>, marketing, and sales     <font color="blue">capabilities</font>, we would be unable to directly <font color="blue">commercialize</font> our <font color="blue">therapeutic</font>s     products which <font color="blue">would limit</font> our <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">technology</font> proves to be <font color="blue">effective</font>, it still may not lead to     <font color="blue">commercially</font>  <font color="blue">viable products</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">collaborators</font> or strategic     partners are successful in using our ZFP <font color="blue">technology</font> in drug <font color="blue">discovery</font>,     <font color="blue">protein production</font>, <font color="blue"><font color="blue">therapeutic</font> <font color="blue">development</font></font>, or <font color="blue">plant <font color="blue">agriculture</font></font>, they may     not be able to <font color="blue">commercialize</font> the resulting products or may decide to use     other <font color="blue">methods <font color="blue">competitive with</font></font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>To date, no company has     received  marketing  approval  or  has developed or <font color="blue">commercialize</font>d any     <font color="blue">therapeutic</font> or <font color="blue">agricultural</font> products <font color="blue">based on</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The failure of     our <font color="blue">technology</font> to provide safe, <font color="blue">effective</font>, useful, or <font color="blue">commercially</font> viable     approaches  to  the  <font color="blue">discovery</font> and <font color="blue">development</font> of these <font color="blue">products would</font>     <font color="blue"><font color="blue">significant</font>ly</font> limit our business and <font color="blue">future growth</font> and <font color="blue">would adversely</font>     affect our value</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">product <font color="blue">development</font></font> efforts are successful and even if the     requisite <font color="blue">regulatory</font> approvals are obtained, our <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>may not     gain <font color="blue">market <font color="blue">acceptance</font></font> among physicians, patients, healthcare payers                                          26       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>A number of <font color="blue">additional</font> factors may limit the     <font color="blue">market <font color="blue">acceptance</font></font> of products including the following:         •  rate of <font color="blue">adoption by healthcare practitioners</font>;         •  rate of a product’s <font color="blue">acceptance</font> by the <font color="blue">target population</font>;         •  timing of <font color="blue">market entry relative</font> to <font color="blue">competitive products</font>;         •  <font color="blue">availability</font> of <font color="blue"><font color="blue">alternative</font> therapies</font>;         •  price of our <font color="blue">product relative</font> to <font color="blue"><font color="blue">alternative</font> therapies</font>;         •  <font color="blue">availability</font> of third-party reimbursement;         •  extent of <font color="blue">marketing efforts by us</font> and third-party distributors or     agents retained by us; and          •  side effects or <font color="blue">unfavorable publicity concerning</font> our products or     similar products</td>
    </tr>
    <tr>
      <td>Adverse events in the field of <font color="blue">gene therapy</font> may <font color="blue"><font color="blue">negatively</font> impact</font> <font color="blue">regulatory</font>     approval or <font color="blue">public perception</font> of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Our potential     <font color="blue"><font color="blue">therapeutic</font> products</font> are delivered to patients as gene-based drugs, or gene     therapy</td>
    </tr>
    <tr>
      <td>The clinical and <font color="blue">commercial success</font> of our <font color="blue">potential products</font> will     depend in part <font color="blue">on public <font color="blue">acceptance</font></font> of the use of <font color="blue">gene therapy</font> for the     prevention  or  treatment  of  <font color="blue">human diseases</font></td>
    </tr>
    <tr>
      <td>Public <font color="blue">attitudes may</font> be     <font color="blue">influenced by</font> claims that <font color="blue">gene therapy</font> is unsafe, and, <font color="blue">consequently</font>, our     <font color="blue">products may</font> not gain the <font color="blue">acceptance</font> of the public or the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">public reaction</font> to <font color="blue">gene therapy</font> in <font color="blue">general could</font> result in greater     <font color="blue">government regulation</font> and stricter labeling <font color="blue">requirements</font> of <font color="blue">gene therapy</font>     products, including any of our products, and could cause a decrease in the     demand for any products we may develop</td>
    </tr>
    <tr>
      <td>Our stock price is also <font color="blue">influenced by</font> <font color="blue">public perception</font></td>
    </tr>
    <tr>
      <td>Reports of serious     <font color="blue">adverse events</font> in a retroviral <font color="blue">gene transfer</font> trial for <font color="blue">infants with</font> X-linked     <font color="blue">severe combined immunodeficiency</font> (X-linked SCID) in France and subsequent     FDA  <font color="blue">actions putting</font> related trials on hold in the <font color="blue">United States</font> had a     <font color="blue"><font color="blue">significant</font> negative impact on</font> the <font color="blue">public perception</font> and stock price of     <font color="blue">certain companies involved</font> in <font color="blue">gene therapy</font></td>
    </tr>
    <tr>
      <td>Stock prices of these companies     <font color="blue">declined whether</font> or not the specific company was <font color="blue">involved with retroviral</font>     gene  transfer  for the treatment of <font color="blue">infants with</font> SCID, or whether the     specific company’s <font color="blue"><font color="blue">clinical trial</font>s</font> were placed on hold in <font color="blue">connection</font> with     these events</td>
    </tr>
    <tr>
      <td>Other potential <font color="blue">adverse events</font> in the field of <font color="blue">gene therapy</font> may occur in the     future that could result in <font color="blue">greater governmental regulation</font> of our potential     products and potential <font color="blue">regulatory</font> delays relating to the testing or approval     of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We are at the <font color="blue">development</font> phase of <font color="blue">operations</font> and may not succeed or become     profitable</td>
    </tr>
    <tr>
      <td>We began <font color="blue">operations</font> in 1995 and are in the <font color="blue">early phases</font> of ZFP     Therapeutic <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred <font color="blue">significant</font> losses</font> and our     net losses for the <font color="blue">past three fiscal years</font> ended 2005, 2004 and 2003 were     dlra13dtta3 million, dlra13dtta8 million and dlra10dtta4 million, respectively</td>
    </tr>
    <tr>
      <td>To date, our     revenues  have <font color="blue">been generated from</font> <font color="blue"><font color="blue">Enabling Technology</font> </font><font color="blue">collaboration</font>s,     <font color="blue">strategic partners</font>, and <font color="blue">federal government research grants</font></td>
    </tr>
    <tr>
      <td>In 2005, we have     placed more emphasis on higher-value <font color="blue">therapeutic</font> <font color="blue">product <font color="blue">development</font></font> and     related <font color="blue">strategic partners</font>hips</td>
    </tr>
    <tr>
      <td>This shift in emphasis has the potential to     increase the <font color="blue">return on investment</font> to our <font color="blue"><font color="blue">stockholders</font> by allocating capital</font>     resources to higher value, <font color="blue">therapeutic</font> <font color="blue">product <font color="blue">development</font></font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>At     the  same time, it increases our <font color="blue">financial risk</font> by increasing expenses     associated  with  <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>In addition, the preclinical or     <font color="blue">clinical failure</font> of any <font color="blue">single product may</font> have a <font color="blue">significant</font> effect on the     actual or perceived value of our shares</td>
    </tr>
    <tr>
      <td>Our business is subject to all of     the <font color="blue">risks inherent</font> in the <font color="blue">development</font> of a new <font color="blue">technology</font>, which include the     need to:         •  attract and retain <font color="blue">qualified scientific</font> and <font color="blue">technical staff</font> and     <font color="blue">management</font>, <font color="blue">particularly</font> scientific staff with expertise to develop our     early-stage <font color="blue">technology</font> into <font color="blue"><font color="blue">therapeutic</font> products</font>;         •  obtain <font color="blue">sufficient capital</font> to support the expense of developing our     <font color="blue">technology</font> platform and developing, testing, and <font color="blue"><font color="blue">commercializing</font> products</font>;         •  develop a market for our products;                                         27       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>    •  <font color="blue">successfully</font> transition from a <font color="blue">company with</font> a <font color="blue">research focus</font> to a     <font color="blue">company capable</font> of <font color="blue">supporting commercial <font color="blue">activities</font></font>; and          •  attract and <font color="blue">enter into</font> research <font color="blue">collaboration</font>s with research and     academic <font color="blue">institutions</font> and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of our <font color="blue">technologies</font> will depend, in part, on strategic     partnering  with other companies</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">find strategic</font>     partners in the future or our <font color="blue">strategic partners</font> do not <font color="blue">diligently pursue</font>     <font color="blue">product <font color="blue">development</font></font> efforts, we may not be able to develop our <font color="blue">technologies</font>     or products, which could slow our growth and decrease our value</td>
    </tr>
    <tr>
      <td>We expect     to rely, to some extent, on our <font color="blue">strategic partners</font> to <font color="blue">provide funding</font> in     support of our research and to perform in<font color="blue">dependent</font> research and preclinical     and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> is <font color="blue">broad based</font>, and we do not currently     possess the resources necessary to fully develop and <font color="blue">commercialize</font> potential     products  that  may  result  from our <font color="blue">technologies</font> or the resources or     <font color="blue">capabilities</font> to complete the lengthy marketing <font color="blue">approval process</font>es that may     be  required for the products</td>
    </tr>
    <tr>
      <td>Therefore, we plan to <font color="blue">rely on strategic</font>     <font color="blue">partnerships</font> to help us develop and <font color="blue">commercialize</font> <font color="blue">ZFP Therapeutic </font>products</td>
    </tr>
    <tr>
      <td>If those partners are unable or unwilling to advance our programs, or if     they do not <font color="blue">diligently pursue</font> product approval, this may slow our progress     and defer our revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">partners may sublicense</font> or abandon <font color="blue">development</font>     programs or we may have <font color="blue">dis<font color="blue"><font color="blue">agreement</font>s</font> with</font> our partners, which would cause     associated <font color="blue">product <font color="blue">development</font></font> to slow or cease</td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will be able to establish <font color="blue">additional</font> strategic <font color="blue">collaboration</font>s for     <font color="blue">ZFP Therapeutic </font><font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>We may require <font color="blue">significant</font> time to     secure <font color="blue">additional</font> <font color="blue">collaboration</font>s or <font color="blue">strategic partners</font> because we need to     <font color="blue">effective</font>ly  market  the  benefits  of  our <font color="blue">technology</font> to these future     <font color="blue">collaborators</font> and <font color="blue">strategic partners</font>, which use the time and efforts of     research  and  <font color="blue">development</font> personnel and our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Further, each     <font color="blue">collaboration</font>  or  strategic  partnering  <font color="blue">arrangement will involve</font> the     <font color="blue">negotiation</font> of terms that may be unique to <font color="blue">each collaborator</font> or strategic     partner</td>
    </tr>
    <tr>
      <td>These  business  <font color="blue">development</font>  efforts  may  not  result in a     <font color="blue">collaboration</font> or <font color="blue">strategic partners</font>hip</td>
    </tr>
    <tr>
      <td>The loss of our current or any future <font color="blue">strategic partnering <font color="blue"><font color="blue">agreement</font>s</font></font> would     not only delay or terminate the potential <font color="blue">development</font> or <font color="blue">commercialization</font>     of products we <font color="blue">may <font color="blue">derive from</font></font> our <font color="blue">technologies</font>, but it <font color="blue">may also delay</font> or     terminate our ability to test ZFP TFs for specific genes</td>
    </tr>
    <tr>
      <td>If any strategic     <font color="blue">partner fail</font>s to conduct the <font color="blue">collaborative</font> <font color="blue">activities</font> <font color="blue">successfully</font> and in a     <font color="blue">timely manner</font>, the preclinical or clinical <font color="blue">development</font> or <font color="blue">commercialization</font>     of the affected product <font color="blue">candidates</font> or <font color="blue">research programs could</font> be delayed or     terminated</td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">strategic partnering <font color="blue"><font color="blue">agreement</font>s</font></font> are <font color="blue">based on</font> the <font color="blue">achievement</font> of     <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>Under the <font color="blue">strategic partnering <font color="blue"><font color="blue">agreement</font>s</font></font>, we expect to receive     revenue for the research and <font color="blue">development</font> of a <font color="blue">ZFP Therapeutic </font>product and     <font color="blue">based on</font> <font color="blue">achievement</font> of specific <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font>these <font color="blue">milestones</font> will     depend, in part, on the efforts of our <font color="blue">strategic partner as well as</font> our own</td>
    </tr>
    <tr>
      <td>In contrast, our historic <font color="blue"><font color="blue">Enabling Technology</font> </font><font color="blue">collaboration</font>s only pay us to     supply ZFP TFs for the collaborator’s in<font color="blue">dependent</font> use, rather than for     future  results of the collaborator’s efforts</td>
    </tr>
    <tr>
      <td>If we, or any strategic     partner, fail to meet specific <font color="blue">milestones</font>, then the <font color="blue">strategic partners</font>hip     may be terminated, which could decrease our revenues</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop, acquire, or market <font color="blue">technologies</font> or products that     are more <font color="blue">effective</font> than ours, this would reduce or eliminate our commercial     <font color="blue">opportunity</font></td>
    </tr>
    <tr>
      <td>Any  products  that we or our <font color="blue">collaborators</font> or strategic     partners develop by using our ZFP <font color="blue">technology</font> platform will <font color="blue">enter into</font> highly     <font color="blue">competitive markets</font></td>
    </tr>
    <tr>
      <td>Even if we are able to generate <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>that     are safe and <font color="blue">effective</font> for their intended use, competing <font color="blue">technologies</font> may     prove to be more <font color="blue">effective</font> or less expensive, which, to the extent these     competing <font color="blue">technologies</font> achieve <font color="blue">market <font color="blue">acceptance</font></font>, will limit our revenue     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>In some cases, competing <font color="blue">technologies</font> have proven to be     satisfactorily <font color="blue">effective</font> and less expensive, as has been the case with     <font color="blue">technologies</font> <font color="blue">competitive with</font> our <font color="blue">Enabling Technology</font>(R)</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">effective</font>ness</font>     of  these <font color="blue">competing products</font> has reduced the revenues <font color="blue">generated by</font> our     <font color="blue">Enabling Technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competing </font><font color="blue">technologies</font> may include other methods of     regulating <font color="blue">gene expression</font> or <font color="blue">modifying genes</font></td>
    </tr>
    <tr>
      <td><font color="blue">ZFP TFs and ZFNs </font>have broad     <font color="blue">application</font> in the <font color="blue">life sciences</font> and <font color="blue">compete with</font> a <font color="blue">broad array</font> of new     <font color="blue">technologies</font>  and approaches being applied to <font color="blue">genetic research by</font> many     companies</td>
    </tr>
    <tr>
      <td><font color="blue">Competing </font><font color="blue">proprietary</font> <font color="blue">technologies</font> with our <font color="blue">product <font color="blue">development</font></font>     focus include:         •  For <font color="blue">ZFP Therapeutics</font>:         •  small molecule drugs;         •  <font color="blue">monoclonal antibodies</font>;                                         28       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>    •  <font color="blue">recombinant proteins</font>;         •  <font color="blue">gene therapy</font> / cDNAs;         •  antisense; and         •  <font color="blue">siRNA approaches</font>         •  For our <font color="blue"><font color="blue">Enabling Technology</font> </font>Applications:         •  For <font color="blue">protein production</font>:  gene amplification, meganucleases, insulator     <font color="blue">technology</font>;         •  For <font color="blue">target validation</font>:  antisense, siRNA; and          •   For  plant  <font color="blue">agriculture</font>:  <font color="blue">recombination</font> approaches, mutagenesis     approaches, meganucleases;         •  In addition to possessing competing <font color="blue">technologies</font>, our <font color="blue">competitors</font>     include bio<font color="blue">technology</font> companies with:         •  substantially greater capital resources than ours;         •  <font color="blue">larger research</font> and <font color="blue">development</font> staffs and <font color="blue">facilities</font> than ours; and         •  greater experience in <font color="blue">product <font color="blue">development</font></font> and in obtaining <font color="blue">regulatory</font>     approvals and <font color="blue">patent protection</font>;         •  These organizations also <font color="blue">compete with</font> us to:         •  <font color="blue">attract qualified personnel</font>;         •  <font color="blue">attract parties</font> for <font color="blue">acquisition</font>s, joint ventures or other     <font color="blue">collaboration</font>s; and          •   license  the  <font color="blue">proprietary</font> <font color="blue">technologies</font> of academic and research     <font color="blue">institutions</font> that are <font color="blue">competitive with</font> our <font color="blue">technology</font>, which may preclude us     <font color="blue">from pursuing</font> similar <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in obtaining <font color="blue">patent protection</font> or     <font color="blue">commercializing</font>  products before us</td>
    </tr>
    <tr>
      <td>In addition, any products that we     develop  may  <font color="blue">compete with</font> existing products or services that are well     established in the marketplace</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> or <font color="blue">strategic partners</font> may decide to <font color="blue">adopt <font color="blue">alternative</font></font>     <font color="blue">technologies</font> or may be unable to develop <font color="blue"><font color="blue">commercially</font> <font color="blue">viable products</font></font> with     our <font color="blue">technology</font>, which would <font color="blue"><font color="blue">negatively</font> impact</font> our revenues and our strategy     to develop these products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> or <font color="blue">strategic partners</font> may     <font color="blue">adopt <font color="blue">alternative</font></font> <font color="blue">technologies</font>, which could decrease the <font color="blue">marketability</font> of     ZFP <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Additionally, because many of our <font color="blue">collaborators</font> or strategic     partners are likely to be working on more than one <font color="blue">development</font> project, they     <font color="blue">could choose</font> to shift their resources to projects other than those they are     working <font color="blue">on with us</font></td>
    </tr>
    <tr>
      <td>If they do so, that would delay our ability to test our     <font color="blue">technology</font>  and  would delay or terminate the <font color="blue">development</font> of potential     products  based  on our ZFP <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">collaborators</font> and     <font color="blue">strategic partners</font> may elect not to develop products arising out of our     <font color="blue">collaborative</font> and <font color="blue">strategic partnering arrangements</font> or to <font color="blue">devote sufficient</font>     resources to the <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing, or sale of these     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not be able to develop our     <font color="blue">technologies</font> or <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We anticipate continuing to incur operating losses for the <font color="blue">next several</font>     years</td>
    </tr>
    <tr>
      <td>If material <font color="blue">losses continue</font> for a <font color="blue">significant</font> period, we may be     unable to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have generated operating <font color="blue">losses since</font>     we began <font color="blue">operations</font> in 1995</td>
    </tr>
    <tr>
      <td>The extent of our <font color="blue">future losses</font> and the timing     of  <font color="blue">profitability</font> are uncertain, and we expect to <font color="blue">incur losses</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have been engaged in developing our ZFP TF <font color="blue">technology</font>     since inception, which has and <font color="blue">will continue</font> to require <font color="blue">significant</font> research     and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2005 we announced that we had     completed  a <font color="blue">registered direct offering</font> to <font color="blue">institutional</font> and strategic     investors for a total of 5cmam080cmam000 shares of <font color="blue"><font color="blue">common stock</font> at</font> a price of     dlra3dtta85 per share to the investors, resulting in net proceeds to Sangamo of     <font color="blue">approximately</font> dlra18dtta2 million</td>
    </tr>
    <tr>
      <td>To date, we have generated all other revenue     from <font color="blue"><font color="blue">Enabling Technology</font> </font><font color="blue">collaboration</font>s, <font color="blue">strategic partnering <font color="blue"><font color="blue">agreement</font>s</font></font>,     and <font color="blue">federal government research grants</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an     <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra110dtta4 million</td>
    </tr>
    <tr>
      <td>We expect to incur     losses for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">losses will increase as</font> we expand     and extend our research and <font color="blue">development</font> <font color="blue">activities</font> into human <font color="blue">therapeutic</font>     <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>If the time required to generate <font color="blue">significant</font> product     revenues and achieve <font color="blue">profitability</font> is longer than we currently anticipate,     we may not be able to sustain our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>We may be unable to raise <font color="blue">additional</font> capital, which would harm our ability     to  develop our <font color="blue">technology</font> and products</td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">significant</font>     operating losses and negative operating <font color="blue">cash flows since inception</font> and have     not  achieved  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We expect <font color="blue">capital outlays</font> and operating     <font color="blue"><font color="blue">expenditure</font>s</font>  to <font color="blue">increase over</font> the <font color="blue"><font color="blue">next several</font> years</font> as we expand our     <font color="blue">infrastructure</font>  and  research  and <font color="blue">ZFP Therapeutic </font><font color="blue">product <font color="blue">development</font></font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>While we believe our <font color="blue"><font color="blue">financial resources</font> will</font> be adequate to     sustain our current <font color="blue">operations</font> at least through 2007, we may seek <font color="blue">additional</font>     sources of <font color="blue">capital through equity</font> or <font color="blue">debt financing</font></td>
    </tr>
    <tr>
      <td>In addition, as we     focus our efforts on <font color="blue">proprietary</font> human <font color="blue">therapeutic</font>s, we will need to seek     FDA approval of <font color="blue">potential products</font>, a process that <font color="blue">could cost</font> in excess of     dlra100 million per product</td>
    </tr>
    <tr>
      <td>We cannot be certain that we will be able to     obtain <font color="blue">financing on terms</font> acceptable to us, or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are     not available, our business and our ability to develop our <font color="blue">technology</font> and     <font color="blue">ZFP Therapeutic </font><font color="blue">products would</font> be harmed</td>
    </tr>
    <tr>
      <td>Our stock price has been volatile and <font color="blue">may continue</font> to be volatile, which     could result in substantial losses for investors</td>
    </tr>
    <tr>
      <td>During the past two     years, our <font color="blue">common stock</font> price has fluctuated <font color="blue"><font color="blue">significant</font>ly</font>, ranging from a     low of dlra3dtta46 to a high of dlra6dtta49 during the year ended <font color="blue">December </font>31, 2005, and     a low of dlra3dtta00 to a high of dlra8dtta02 during the year ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td><font color="blue">Volatility </font>in our <font color="blue">common stock</font> could cause <font color="blue">stockholders</font> to incur substantial     losses</td>
    </tr>
    <tr>
      <td>An <font color="blue">active public market</font> for our <font color="blue"><font color="blue">common stock</font> may</font> not be sustained,     and the <font color="blue">market price</font> of our <font color="blue">common stock</font> <font color="blue">may continue</font> to be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>The  market  price of our <font color="blue">common stock</font> has fluctuated <font color="blue"><font color="blue">significant</font>ly</font> in     response to the <font color="blue">following factors</font>, some of which are beyond our control:         •  <font color="blue">announcements by us</font> or our <font color="blue">partners providing updates on</font> the progress     or <font color="blue">development</font> status of <font color="blue">ZFP Therapeutics</font>;         •  changes in <font color="blue">market valuations</font> of similar companies;         •  <font color="blue">deviations</font> in our results of <font color="blue">operations</font> from the <font color="blue">guidance given by us</font>     or estimates of <font color="blue">securities analysts</font>;         •  <font color="blue">announcements by us</font> or our <font color="blue">competitors</font> of new or <font color="blue">enhanced products</font>,     <font color="blue">technologies</font> or services or <font color="blue">significant</font> contracts, <font color="blue">acquisition</font>s, strategic     <font color="blue">relationships</font>, joint ventures or capital <font color="blue">commitments</font>;         •  <font color="blue">regulatory</font> <font color="blue">development</font>s;         •  <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>;         •  <font color="blue">future sales</font> of our <font color="blue">common stock</font> or other <font color="blue">securities by</font> the company,     <font color="blue">management</font> or <font color="blue">directors</font>, liquidation of <font color="blue">institutional</font> funds that comprised     large holdings of Sangamo stock; and         •  <font color="blue">decreases</font> in our <font color="blue">cash balances</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is thinly traded, which means large <font color="blue">transactions</font> in our     <font color="blue"><font color="blue">common stock</font> may</font> be <font color="blue">difficult</font> to conduct in a short time frame</td>
    </tr>
    <tr>
      <td>We have a     low  volume of <font color="blue">daily trades</font> in our <font color="blue">common stock</font> on the Nasdaq National     Market</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">average daily trading volume</font> in our <font color="blue">common stock</font> on     the  Nasdaq  National  Market over the ten-day trading period prior to     <font color="blue">February </font>1,  2006  was <font color="blue">approximately</font> 101cmam000 shares per day</td>
    </tr>
    <tr>
      <td>Any large     <font color="blue">transactions</font> in our <font color="blue"><font color="blue">common stock</font> may</font> be <font color="blue">difficult</font> to conduct and may cause     <font color="blue">significant</font> fluctuations in the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Failure to attract, retain, and motivate skilled personnel and cultivate key     academic <font color="blue">collaboration</font>s will delay our <font color="blue">product <font color="blue">development</font></font> programs and our     research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We are a small <font color="blue">company with</font> 62 full-time     <font color="blue">employees as</font> of <font color="blue">February </font>14, 2006 and our <font color="blue">success depends on</font> our continued     ability to attract, retain, and motivate highly qualified <font color="blue">management</font> and     <font color="blue">scientific personnel</font> and our ability to develop and maintain important     <font color="blue">relationships</font>  with  leading  research  and  academic <font color="blue">institutions</font> and     <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for personnel and academic and other research     <font color="blue">collaboration</font>s  is  intense</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">technology</font> <font color="blue">development</font>     programs  depends  on our ability to attract and retain <font color="blue">highly trained</font>     personnel  and we have experienced a rate of <font color="blue">employee turnover</font> that we     believe is typical of emerging bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>If we lose the     services of <font color="blue">personnel with</font> the <font color="blue">necessary skills</font>, it could <font color="blue"><font color="blue">significant</font>ly</font>     impede the <font color="blue">achievement</font> of our research and <font color="blue">development</font> objectives</td>
    </tr>
    <tr>
      <td>We are     not  presently  aware  of any plans of <font color="blue">specific employees</font> to retire or     <font color="blue">otherwise leave</font> the company</td>
    </tr>
    <tr>
      <td>If we fail to negotiate <font color="blue">additional</font> acceptable     <font color="blue">collaboration</font>s with academic and other research <font color="blue">institutions</font> and <font color="blue">scientists</font>,     or if our existing <font color="blue">collaboration</font>s are <font color="blue">unsuccessful</font>, our <font color="blue">ZFP Therapeutic </font>    <font color="blue">development</font> programs may be delayed or may not succeed</td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>If conflicts arise <font color="blue">between us</font> and our <font color="blue">collaborators</font>, <font color="blue">strategic partners</font>,     scientific  advisors,  or  <font color="blue">directors</font>,  these  <font color="blue">parties may</font> act in their     self-interest, which may limit our ability to implement our strategies</td>
    </tr>
    <tr>
      <td>If     conflicts arise between our corporate or academic <font color="blue">collaborators</font>, strategic     partners, or <font color="blue">scientific advisors</font> or <font color="blue">directors</font> and us, the other party may     act in its self-interest, which may limit our ability to implement our     strategies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">license <font color="blue">agreement</font> with</font> <font color="blue">Edwards Lifesciences </font>provides <font color="blue">Edwards     </font>with worldwide, <font color="blue">exclusive rights</font> for <font color="blue"><font color="blue">ZFP Therapeutics</font> </font>“for the <font color="blue">activation</font> of     VEGF  and  VEGF <font color="blue">receptors</font> for the treatment and prevention of ischemic     <font color="blue">cardiovascular</font> and <font color="blue">vascular disease</font> in humans</td>
    </tr>
    <tr>
      <td>” We have retained all rights     to use our <font color="blue">technology</font> for all <font color="blue">therapeutic</font> <font color="blue">application</font>s of VEGF <font color="blue">activation</font>     outside of the treatment and prevention of ischemic <font color="blue">cardiovascular</font> and     vascular  disease in humans</td>
    </tr>
    <tr>
      <td>During the first quarter of 2005, <font color="blue">Sangamo     </font>commenced a Phase 1 <font color="blue">clinical trial</font> for the treatment of diabetic <font color="blue">neuropathy</font>     using a <font color="blue">ZFP Therapeutic </font>for the <font color="blue">activation</font> of <font color="blue">VEGF Edwards </font>has stated that     its rights include diabetic <font color="blue">neuropathy</font> and <font color="blue">consequently</font> our <font color="blue">activities</font>     relating to diabetic <font color="blue">neuropathy</font> constitute a breach of the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">strongly disagree with</font> the Edwards’ assertion because diabetic <font color="blue">neuropathy</font> is     a <font color="blue">neurological disease</font> and not an ischemic <font color="blue">vascular disease</font> and therefore is     outside  the  scope of the Edwards license</td>
    </tr>
    <tr>
      <td><font color="blue">Sangamo and Edwards </font>are in     <font color="blue">discussions</font> regarding this issue</td>
    </tr>
    <tr>
      <td>Some of our academic <font color="blue">collaborators</font> and     <font color="blue">strategic partners</font> are conducting multiple <font color="blue">product <font color="blue">development</font></font> efforts     within each area that is the subject of the <font color="blue">collaboration</font> with us</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> or <font color="blue">strategic partners</font>, however, may develop, <font color="blue">either alone</font> or     with  others, products in related fields that are <font color="blue">competitive with</font> the     products or <font color="blue">potential products</font> that are the subject of these <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Competing </font>products, either developed by the <font color="blue">collaborators</font> or strategic     partners or to which the <font color="blue">collaborators</font> or <font color="blue">strategic partners</font> have rights,     may result in the withdrawal of <font color="blue">partner support</font> for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Some  of  our  <font color="blue">collaborators</font>  or  <font color="blue">strategic partners</font> could also become     <font color="blue">competitors</font> in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> or <font color="blue">strategic partners</font> could     develop <font color="blue">competing products</font>, preclude us from entering into <font color="blue">collaboration</font>s     with  their  <font color="blue">competitors</font>,  fail to obtain timely <font color="blue">regulatory</font> approvals,     terminate their <font color="blue"><font color="blue">agreement</font>s</font> with us prematurely, or fail to <font color="blue">devote sufficient</font>     resources to the <font color="blue">development</font> and <font color="blue">commercialization</font> of products</td>
    </tr>
    <tr>
      <td>Any of these     <font color="blue">development</font>s could harm our <font color="blue">product <font color="blue">development</font></font> efforts</td>
    </tr>
    <tr>
      <td>Because it is <font color="blue">difficult</font> and costly to protect our <font color="blue">proprietary</font> rights, and     <font color="blue">third parties</font> have filed patent <font color="blue">application</font>s that are similar to ours, we     cannot  ensure  the  <font color="blue">proprietary</font>  protection  of  our <font color="blue">technologies</font> and     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> will depend in part on obtaining patent     protection of our <font color="blue">technology</font> and <font color="blue">successfully</font> defending any of our patents     which  may  be  challenged</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies can be <font color="blue">highly uncertain</font> and can <font color="blue">involve complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> regarding the breadth of     claims allowed in bio<font color="blue">technology</font> patents has emerged to date</td>
    </tr>
    <tr>
      <td>Accordingly, we     <font color="blue">cannot predict</font> the breadth of claims allowed in patents we own or license</td>
    </tr>
    <tr>
      <td>We are a party to various license <font color="blue"><font color="blue">agreement</font>s</font> that <font color="blue">give us rights under</font>     <font color="blue">specified patents</font> and patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Our current licenses, as our     future licenses frequently will, contain performance <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we fail     to meet those <font color="blue">obligations</font>, the <font color="blue">licenses could</font> be terminated</td>
    </tr>
    <tr>
      <td>If we are     unable to continue to license these <font color="blue">technologies</font> on <font color="blue">commercially</font> reasonable     terms,  or  at all, we may be forced to delay or terminate our product     <font color="blue">development</font> and research <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>With respect to our present and any future sublicenses, since our rights     <font color="blue">derive from</font> those granted to our <font color="blue">sublicensor</font>, we are subject to the risk     that our <font color="blue">sublicensor</font> may fail to perform its <font color="blue">obligations</font> under the master     license or fail to <font color="blue">inform us</font> of <font color="blue">useful improvements</font> in, or <font color="blue">additions</font> to, the     <font color="blue">underlying <font color="blue">intellectual</font> property</font> owned by the <font color="blue">original licensor</font></td>
    </tr>
    <tr>
      <td>We are unable to exercise the same degree of <font color="blue">control over <font color="blue">intellectual</font></font>     property  that  we  license from <font color="blue">third parties</font> as we <font color="blue">exercise over</font> our     <font color="blue">internally</font>  developed  <font color="blue">intellectual</font>  property</td>
    </tr>
    <tr>
      <td>We  do not control the     <font color="blue">prosecution</font> of certain of the patent <font color="blue">application</font>s that we <font color="blue">license from third</font>     parties; therefore, the patent <font color="blue">application</font>s may not be <font color="blue">prosecuted exactly as</font>     we desire or in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">future protection</font> for our <font color="blue">proprietary</font> rights is uncertain, and     we <font color="blue">cannot ensure</font> that:         •  we or our <font color="blue">licensors</font> were the first to make the <font color="blue">inventions</font> covered by     each of our pending patent <font color="blue">application</font>s;         •  we or our <font color="blue">licensors</font> were the first to file patent <font color="blue">application</font>s for     these <font color="blue">inventions</font>;         •  the patents of <font color="blue">others will</font> not have an adverse effect on our ability to     do business;                                         31       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>    •  <font color="blue">others will</font> not in<font color="blue">dependent</font>ly develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or <font color="blue">reverse engineer</font> any of our products, processes or     <font color="blue">technologies</font>;         •  any of our pending patent <font color="blue">application</font>s will result in <font color="blue">issued patents</font>;         •  any <font color="blue">patents issued</font> or licensed to us or our <font color="blue">collaborators</font> or strategic     <font color="blue">partners <font color="blue">will provide</font></font> a basis for <font color="blue"><font color="blue">commercially</font> <font color="blue">viable products</font></font> or will     <font color="blue">provide us with</font> any <font color="blue">competitive advantages</font>;          •   any <font color="blue">patents issued</font> or licensed to us will not be challenged and     invalidated by <font color="blue">third parties</font>; or         •  we will develop <font color="blue">additional</font> products, processes or <font color="blue">technologies</font> that are     patentable</td>
    </tr>
    <tr>
      <td>Others have filed and in the future are likely to file patent <font color="blue">application</font>s     that are similar to ours</td>
    </tr>
    <tr>
      <td>We are aware that there are <font color="blue">academic groups</font> and     other companies that are attempting to develop <font color="blue">technology</font> that is <font color="blue">based on</font>     the use of zinc finger and other DNA <font color="blue">binding proteins</font>, and that these groups     and companies have filed patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Several patents have been     issued, although we have no current plans to use the associated <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>If these or other patents issue, it is possible that the holder of any     patent or <font color="blue">patents <font color="blue">granted on</font></font> these <font color="blue">application</font>s may bring an <font color="blue">infringement</font>     <font color="blue">action against</font> our <font color="blue">collaborators</font>, <font color="blue">strategic partners</font>, or us claiming damages     and  seeking  to enjoin commercial <font color="blue">activities</font> relating to the affected     products  and  processes</td>
    </tr>
    <tr>
      <td>Moreover, we <font color="blue">cannot predict</font> whether we, our <font color="blue">collaborators</font>, or     strategic  partners  <font color="blue">would prevail</font> in any actions</td>
    </tr>
    <tr>
      <td>In addition, if the     <font color="blue">relevant patent</font> claims were <font color="blue">upheld as valid</font> and enforceable and our products     or processes were found to infringe the patent or patents, we could be     <font color="blue">prevented from</font> making, using, or selling the <font color="blue">relevant product</font> or process     unless we could obtain a license or were able to <font color="blue">design around</font> the patent     claims</td>
    </tr>
    <tr>
      <td>We can <font color="blue">give no assurance</font> that such a <font color="blue">license would</font> be <font color="blue">available on</font>     <font color="blue">commercially</font>  <font color="blue">reasonable terms</font>, or at all, or that we would be able to     <font color="blue">successfully</font>  design  around  the <font color="blue">relevant patent</font> claims</td>
    </tr>
    <tr>
      <td>There may be     <font color="blue">significant</font> <font color="blue">litigation</font> in the <font color="blue">genomics industry</font> regarding patent and other     <font color="blue">intellectual</font> property rights, which could subject us to <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If we     <font color="blue">become involved</font> in <font color="blue">litigation</font>, it <font color="blue">could consume</font> a substantial portion of our     managerial and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that <font color="blue">third parties</font> will not challenge our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>One of our licensed patents, European Patent Nodtta 0 682 699,     entitled “Functional Domains in Flavobacterium Okeanokoites Restriction     Endonuclease” was <font color="blue">granted on</font> May 7, 2003 and forms the basis of Regional     Phase patents in France, Germany, Great Britain, Ireland and Switzerland</td>
    </tr>
    <tr>
      <td>The granted claims of the patent cover <font color="blue">technologies</font> used in our programs in     targeted  <font color="blue">recombination</font>  and  gene  <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>1, 2005 an     <font color="blue">interlocutory decision revoking</font> this patent was issued by the European     Patent Office</td>
    </tr>
    <tr>
      <td>If our appeal is ultimately     <font color="blue">unsuccessful</font>, our ability to exclude potential <font color="blue">competitors</font> in the field of     targeted <font color="blue">recombination</font> and gene <font color="blue">correction</font> <font color="blue">in Europe </font>may be limited</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">development</font>s apply only to Europe and do not affect our ability to practice     our targeted <font color="blue">recombination</font> and gene <font color="blue">correction</font> programs in Europe</td>
    </tr>
    <tr>
      <td>Moreover,     we also hold licenses to six US patents to the <font color="blue">technology</font> covered by the     opposed European patent, and hold licenses to related <font color="blue">application</font>s pending     in <font color="blue">Canada and Japan</font></td>
    </tr>
    <tr>
      <td>Accordingly, any effects of the opposition, up to and     including <font color="blue">invalidation</font> <font color="blue">of the European </font>patent, would be restricted to <font color="blue">Europe     </font>and would have little, if any, material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> to protect <font color="blue">technology</font> where we believe patent     protection is not <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>Trade secrets, however, are     <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>While we require employees, academic <font color="blue">collaborators</font>,     and <font color="blue">consultants</font> to <font color="blue">enter into</font> <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font>, we may not be able     to <font color="blue">adequately protect</font> our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information or     enforce these <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font>, <font color="blue">strategic partners</font>, and <font color="blue">scientific advisors</font> have rights     to <font color="blue">publish data</font> and information in which we may have rights</td>
    </tr>
    <tr>
      <td>If we cannot     maintain  the <font color="blue">confidential</font>ity of our <font color="blue">technology</font> and other <font color="blue">confidential</font>     information  in  <font color="blue">connection</font>  with  our  <font color="blue">collaboration</font>s  and  strategic     <font color="blue">partnerships</font>,  then we may not be able to receive <font color="blue">patent protection</font> or     protect our <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font> approval,  if  granted, may be limited to <font color="blue">specific uses</font> or     geographic   areas,   which   could  limit  our  ability  to  generate     revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">approval will</font> be limited to the <font color="blue">indicated use</font> for     which we can market a product</td>
    </tr>
    <tr>
      <td>Further, once <font color="blue">regulatory</font> approval for a     product  is  obtained, the product and its <font color="blue">manufacture</font>r are subject to     <font color="blue">continual review</font></td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>of <font color="blue">previously</font> unknown problems with a product or     <font color="blue">manufacture</font>r may result in <font color="blue">restrictions</font> on the product, <font color="blue">manufacture</font>r, and     <font color="blue">manufacturing</font> <font color="blue">facility</font>, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>In Japan and Europe, <font color="blue">regulatory</font> agencies also set or <font color="blue">approve prices</font></td>
    </tr>
    <tr>
      <td>32       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font>Even if <font color="blue">regulatory</font> clearance of a product is granted, this clearance is     limited to those specific states and <font color="blue">conditions</font> for which the product is     useful, as <font color="blue">demonstrate</font>d <font color="blue">through <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that any     <font color="blue">ZFP Therapeutic </font>product developed by us, alone or with others, will prove to     be safe and <font color="blue">effective</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> and will meet all of the applicable     <font color="blue">regulatory</font> <font color="blue">requirements</font> needed to receive <font color="blue">marketing clearance</font> in a given     country</td>
    </tr>
    <tr>
      <td>Outside the <font color="blue">United States</font>, our ability to market a product is <font color="blue">contingent</font>     upon receiving a <font color="blue">marketing authorization from</font> the <font color="blue">appropriate</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font>, so we <font color="blue">cannot predict</font> whether or when we would be permitted to     <font color="blue">commercialize</font> our product</td>
    </tr>
    <tr>
      <td>These foreign <font color="blue">regulatory</font> <font color="blue">approval process</font>es     include all of the <font color="blue">risks associated with</font> FDA <font color="blue">clearance described</font> above</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaboration</font>s with outside <font color="blue">scientists</font> may be subject to change, which     <font color="blue">could limit</font> our access to their expertise</td>
    </tr>
    <tr>
      <td>We work with <font color="blue">scientific advisors</font>     and <font color="blue">collaborators</font> at academic research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">scientists</font> are     not our employees and may have other <font color="blue">commitments</font> that <font color="blue">would limit</font> their     <font color="blue">availability</font> to us</td>
    </tr>
    <tr>
      <td>Although our <font color="blue">scientific advisors</font> generally agree not to     do competing work, if a conflict of <font color="blue">interest between</font> their work for us and     their work for another entity arises, we may lose their services</td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>our <font color="blue">scientific advisors</font> and academic <font color="blue">collaborators</font> sign <font color="blue"><font color="blue">agreement</font>s</font> not to     disclose our <font color="blue">confidential</font> information, it is possible that some of our     valuable <font color="blue">proprietary</font> knowledge may become publicly known through them</td>
    </tr>
    <tr>
      <td>Laws or public sentiment may limit the production of <font color="blue">genetically</font> modified     <font color="blue">agricultural</font>  products  in the future, and these <font color="blue">laws <font color="blue">could reduce</font></font> our     partner’s ability to sell these products</td>
    </tr>
    <tr>
      <td><font color="blue">Genetically </font><font color="blue">modified products</font> are     currently subject to <font color="blue">public debate</font> and heightened <font color="blue">regulatory</font> scrutiny,     either of <font color="blue">which could prevent</font> or <font color="blue">delay production</font> of <font color="blue">agricultural</font> products</td>
    </tr>
    <tr>
      <td><font color="blue">Effective </font>as of October 1, 2005, we <font color="blue">entered into</font> a <font color="blue">Research License </font>and     <font color="blue">Commercial Option Agreement </font>with Dow AgroSciences LLC (“DAS”), a wholly     owned indirect subsidiary <font color="blue">of Dow Chemical Corporation</font></td>
    </tr>
    <tr>
      <td>Under this <font color="blue">agreement</font>,     we <font color="blue">will provide</font> DAS with access to our <font color="blue">proprietary</font> ZFP <font color="blue">technology</font> and the     exclusive right to use our ZFP <font color="blue">technology</font> to modify the genomes or alter the     <font color="blue">nucleic acid</font> or <font color="blue">protein expression</font> of plant cells, plants, or plant cell     cultures</td>
    </tr>
    <tr>
      <td>The field-testing, production, and marketing of <font color="blue">genetically</font>     <font color="blue">modified plants</font> and <font color="blue">plant products</font> are subject to federal, state, local, and     <font color="blue">foreign governmental regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies administering existing</font>     or <font color="blue">future regulations</font> or <font color="blue">legislation may</font> not <font color="blue">allow production</font> and marketing     of our <font color="blue">genetically</font> <font color="blue">modified products</font> in a <font color="blue">timely manner</font> or <font color="blue">under technically</font>     or <font color="blue">commercially</font> feasible <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">regulatory</font> action or     private <font color="blue">litigation</font> could result in expenses, delays, or other <font color="blue">impediments</font> to     our <font color="blue">product <font color="blue">development</font></font> programs or the <font color="blue">commercialization</font> of resulting     products</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">currently applies</font> the same <font color="blue">regulatory</font> standards to foods developed     through genetic engineering as those applied to foods developed through     <font color="blue">traditional plant breeding</font></td>
    </tr>
    <tr>
      <td><font color="blue">Genetically </font>engineered food products, however,     will  be  subject  to pre-market review if these <font color="blue">products raise safety</font>     questions or are deemed to be <font color="blue">food additives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">authorities</font> could     also, for social or other purposes, limit the use of <font color="blue">genetically</font> modified     products created with our <font color="blue">gene regulation</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Even if we are able to obtain <font color="blue">regulatory</font> approval for <font color="blue">genetically</font> modified     products, our success will also depend <font color="blue">on public <font color="blue">acceptance</font></font> of the use of     <font color="blue">genetically</font> <font color="blue">modified products</font> including drugs, plants, and <font color="blue">plant products</font></td>
    </tr>
    <tr>
      <td>Claims that <font color="blue">genetically</font> <font color="blue">modified products</font> are unsafe for <font color="blue">consumption</font> or pose     a danger to the <font color="blue">environment may influence public attitudes</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">genetically</font>     modified <font color="blue">products may</font> not gain public <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The subject of <font color="blue">genetically</font>     <font color="blue">modified organisms</font> has received <font color="blue">negative publicity</font> in the <font color="blue">United States</font> and     <font color="blue">particularly</font> in Europe, and such publicity has aroused <font color="blue">public debate</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">adverse publicity</font> <font color="blue">in Europe </font>could lead to <font color="blue">greater regulation</font> and trade     <font color="blue">restrictions</font> on imports of <font color="blue">genetically</font> altered products</td>
    </tr>
    <tr>
      <td>Similar adverse     <font color="blue">public reaction</font> in the <font color="blue">United States</font> to genetic research and its resulting     products could result in greater domestic regulation and could decrease the     demand for our <font color="blue">technology</font> and products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">use biological</font> and <font color="blue">hazardous materials</font> in a manner that causes injury     or  violates  laws,  we  may  be liable for damages</td>
    </tr>
    <tr>
      <td>Our research and     <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of <font color="blue">potentially harmful</font>     biological materials as well as <font color="blue">hazardous materials</font>, chemicals, and various     <font color="blue">radioactive compounds typically employed</font> in molecular and <font color="blue">cellular biology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">routinely use cells</font> in culture and <font color="blue">gene delivery vectors</font>, and we employ     small amounts of <font color="blue">radioisotopes</font> in <font color="blue">trace experiments</font></td>
    </tr>
    <tr>
      <td>Although we maintain     up-to-date licensing and <font color="blue">training programs</font>, we <font color="blue">cannot completely eliminate</font>     the  risk of <font color="blue">accidental <font color="blue">contamination</font></font> or <font color="blue">injury from</font> the use, storage,     handling, or disposal of these materials</td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">contamination</font> or     injury, we could be held liable for damages that result, and any <font color="blue">liability</font>     <font color="blue">could exceed</font> our resources</td>
    </tr>
    <tr>
      <td>We currently carry <font color="blue">insurance covering</font> claims     arising from our use of                                         33       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>these  materials</td>
    </tr>
    <tr>
      <td>However, if we are unable to maintain our insurance     coverage at a <font color="blue">reasonable cost</font> and <font color="blue">with adequate coverage</font>, our <font color="blue">insurance may</font>     not cover any <font color="blue">liability</font> that may arise</td>
    </tr>
    <tr>
      <td>We are subject to federal, state,     and <font color="blue">local laws</font> and <font color="blue">regulations governing</font> the use, storage, handling, and     disposal of these materials and <font color="blue">specified waste products</font></td>
    </tr>
    <tr>
      <td>To date, we have     not experienced <font color="blue">significant</font> costs in <font color="blue">complying with regulations</font> regarding     the use of these materials</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue"><font color="blue">Delaware </font>    </font>law  could make an <font color="blue">acquisition</font> of the Company more <font color="blue">difficult</font> and could     prevent  attempts  by  our  <font color="blue">stockholders</font>  to remove or <font color="blue">replace current</font>     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions of <font color="blue">Delaware </font>law, our <font color="blue">certificate</font> of     <font color="blue">incorporation</font> and our bylaws and may discourage, delay or prevent a change     in control of our company, even if a change in <font color="blue">control would</font> be <font color="blue">beneficial</font>     to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">provisions may frustrate</font> or prevent     any <font color="blue">attempts by</font> our <font color="blue">stockholders</font> to replace or remove our current <font color="blue">management</font>     by making it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to <font color="blue">replace members</font> of our board     of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In particular, under our <font color="blue">certificate</font> of <font color="blue">incorporation</font> our     board of <font color="blue">directors</font> may issue up to 5cmam000cmam000 shares of <font color="blue"><font color="blue">preferred stock</font> with</font>     rights and privileges that might be senior to our <font color="blue">common stock</font>, without the     consent of the holders of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Moreover, without any further     vote or <font color="blue">action on</font> the part of the <font color="blue">stockholders</font>, the board of <font color="blue">directors</font> would     have the authority to determine the price, rights, preferences, privileges,     and <font color="blue">restrictions</font> of the <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">preferred stock</font>, if it is ever     issued, may have <font color="blue">preference over</font>, and harm the rights of, the holders of     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Although the issuance of this <font color="blue">preferred stock</font> would provide us     with  <font color="blue">flexibility</font>  in  <font color="blue">connection</font> with possible <font color="blue">acquisition</font>s and other     <font color="blue">corporate purposes</font>, this <font color="blue">issuance may</font> make it more <font color="blue">difficult</font> for a third     party to acquire a majority of our <font color="blue">outstanding <font color="blue">voting stock</font></font></td>
    </tr>
    <tr>
      <td>Similarly, our     authorized  but unissued <font color="blue">common stock</font> is available for <font color="blue">future issuance</font>     <font color="blue">without stockholder approval</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">certificate</font> of <font color="blue">incorporation</font>:         •  states that <font color="blue">stockholders</font> may not act <font color="blue">by written consent but only at</font> a     <font color="blue">stockholders</font>’ meeting;         •  <font color="blue">establishes advance</font> notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for election to     the  board of <font color="blue">directors</font> or <font color="blue">proposing matters</font> that can be acted upon at     <font color="blue">stockholders</font>’ meetings; and         •  limits who may call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We are also subject to Section 203 of the <font color="blue">Delaware </font>General Corporation Law,     <font color="blue">which provides</font>, subject to <font color="blue">certain exceptions</font>, that if a person acquires 15prca     of our <font color="blue">voting stock</font>, the person is an “<font color="blue">interested stockholder</font>” and may not     engage in “business combinations” with us for a period of <font color="blue">three years from</font>     the time the person acquired 15prca or more or our <font color="blue">voting stock</font></td>
    </tr>
    <tr>
      <td>The interest of <font color="blue">management</font> could <font color="blue">conflict with</font>     the interest of our other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">executive officers</font> and <font color="blue">directors</font>     <font color="blue">beneficial</font>ly own, in the aggregate, <font color="blue">approximately</font> 21prca of our outstanding     common  stock</td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">stockholders</font>, if they choose to act     together, will be able to have a material impact on all matters requiring     stockholder approval, including the election of <font color="blue">directors</font> and approval of     <font color="blue">significant</font> corporate <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>This could have the effect of delaying     or preventing a change of control of Sangamo, which in turn <font color="blue">could reduce</font> the     <font color="blue">market price</font> of our stock</td>
    </tr>
  </tbody>
</table>